UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000043218
Receipt number R000049319
Scientific Title VR-CBT for Rumination (Single arm, Prospective Interventional Study)
Date of disclosure of the study information 2021/02/01
Last modified on 2022/08/03 01:16:04

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

VR-CBT for Rumination

Acronym

VR-CBT for Rumination

Scientific Title

VR-CBT for Rumination (Single arm, Prospective Interventional Study)

Scientific Title:Acronym

VR-CBT for Rumination

Region

Japan


Condition

Condition

rumination

Classification by specialty

Psychosomatic Internal Medicine Psychiatry

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

This study is aimed to test the effectiveness of VR-based cognitive behavioral therapy on people suffering from rumination. The participants will experience distancing themselves from the emotions and behaviors behind rumination through the third-generation cognitive-behavioral therapy using VR, and we will evaluate whether the images experienced in VR can be fixed, suppress the appearance of rumination, and reduce depression.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Rumination: Repetitive Thinking Questionnaire

Key secondary outcomes

Depression: Self-rating Depression Scale
Frequency of occurrence of rumination and psychological burden caused by rumination


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Educational,Counseling,Training

Type of intervention

Behavior,custom

Interventions/Control_1

In addition to regular medical care, VR-CBT will be conducted; VR-CBT will be conducted in a total of five sessions.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)Those who are 18 years old or older at the time of obtaining consent
2)Rumination is observed.
3)Applicants who are able to wear VR goggles.
4)Those who are able to understand instructions in Japanese necessary for conducting research.

Key exclusion criteria

1)When it is judged that it is difficult to carry out the research due to a medical condition.
2)Those who have difficulty wearing VR goggles due to sensory sensitivity, etc.

Target sample size

30


Research contact person

Name of lead principal investigator

1st name Hiroki
Middle name
Last name Okada

Organization

Kumegawa Hospital

Division name

Psycho-somatic Internal Medicine

Zip code

761-0102

Address

Koh 474-3, Shinden-cho, Takamatsu, Kagawa, Japan

TEL

087-844-3111

Email

okadaedu@med.kagawa-u.ac.jp


Public contact

Name of contact person

1st name Masayo
Middle name
Last name Matsumura

Organization

BiPSEE, Inc.

Division name

Research Department

Zip code

160-0004

Address

4-28-7, Yotsuya, Shinku-ku, Tokyo, Japan

TEL

03-6555-3012

Homepage URL


Email

m.matsumura@bipsee.co.jp


Sponsor or person

Institute

BiPSEE, Inc.

Institute

Department

Personal name



Funding Source

Organization

BiPSEE, Inc.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Review Board, Foundation for Health and Preventive Medicine

Address

3-6-17, Nakamachi, Atsugi, Kanagawa, Japan

Tel

046-206-2112

Email

y.sakurai@h-p-m.org


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 02 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed

Delay expected

Results Delay Reason

Due to the time required to process and analyze the data

Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2020 Year 12 Month 28 Day

Date of IRB

2020 Year 12 Month 28 Day

Anticipated trial start date

2021 Year 01 Month 13 Day

Last follow-up date

2021 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2021 Year 02 Month 01 Day

Last modified on

2022 Year 08 Month 03 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049319


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name